Presentation will highlight data demonstrating the non-sedating effects of tolperisone
SAN DIEGO, Oct. 17, 2018 – Neurana Pharmaceuticals, a specialty pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that data from a Phase 1 clinical study demonstrating the non-sedating effects of tolperisone in a simulated driving performance and cognitive functioning assessment in healthy adult volunteers will be presented at the American College of Emergency Physicians (ACEP) October 1-4, 2018 in San Diego, California.
"We look forward to sharing the results of this Phase 1 clinical driving simulation study at this important meeting," said Craig Thompson, President and Chief Executive Officer of Neurana. "The clinical data we will present at ACEP supports our commitment to advancing the development of tolperisone as a novel treatment for potentially treating acute painful muscle spasms in the United States and Canada."
The ACEP18 presentation by Neurana Pharmaceuticals is as follows:
Title: No Evidence of Sedation of Tolperisone Compared to Cyclobenzaprine in a Crossover Driving Simulation Study Abstract Presentation: 276 Date and Time: Tuesday, October 2, 2018 at 5:00-6:00 pm (Pacific) Session: ACEP Research Forum
About Tolperisone Tolperisone is approved and widely used in Europe and Asia for the treatment of neuromuscular conditions. It has been shown to be safe and effective in treating neuromuscular conditions and non-sedating, a side effect most commonly seen with other muscle relaxants.
Neurana is preparing to commence a Phase 2 dose-ranging clinical study to further demonstrate the safety and efficacy of tolperisone in subjects with acute, painful muscle spasms of the back.
About Neurana Pharmaceuticals, Inc. Neurana Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the neck and back and spasticity. Neurana is developing tolperisone, a novel therapeutic compound that has demonstrated efficacy and safety in the treatment of significant musculoskeletal conditions. For additional information please visit us at neuranapharma.com.
Contact: For additional information, please contact: Business Development, Neurana Pharmaceuticals email@example.com